Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus
Open accessThe DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Management of patients with opioid use disorder (OUD) commonly includes opioid agonist therapy (OAT) as a part of an integrated treatment plan. These interventions are associated with proven benefits to the individual and society. Areas covered: The use of methadone and buprenorphine within an integrated treatment plan in the management of patients with OUD: this work provides consensus recommendation on pharmacotherapy in OUD to assist clinicians with practical decision making in this field. Expert opinion: Pharmacotherapy is recommended as part of an integrated OUD treatment approach with psychosocial interventions, with the goal of reducing risks of illicit opioid use, overdose mortality, infection with HIV or HCV, improving health, psychological and social outcomes. Access to OAT should be prioritised in the treatment of OUD. Treatment choices in OUD pharmacotherapy should be based on the needs of the individual and characteristics of medications. Recommendations for choices of OAT are based on clinical efficacy, safety, patient preference, side effects, pharmacological interactions, quality of life, dose titration potential and outcomes (control craving, ongoing opioids consumption or other drugs, and potentially psychiatric comorbidities). Special groups, pregnant women, prisoners, patients with mental health problems have specific needs which must be addressed with expert input.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For both buprenorphine and methadone, the impact on craving is dose dependent (112, 113), and it is clear that in order to adequately suppress craving, buprenorphine and methadone must be carefully up-titrated to achieve the optimal dose for each patient (7).”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [7]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816 · cited 2×
“including opioid agonist medication, is associated with important social and clinical benefits, reduces overdose deaths and crime, increases quality of life [6,7], and enables patients to”
BackgroundDSM-5 criteria for substance use disorders: recommendations and rationale
Hasin, D. S., O’Brien, C. P., Auriacombe, M., Borges, G., Bucholz, K., Budney, A., Compton, W. M., Crowley, T., Ling, W., Petry, N. M., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12060782 · Cited by 1,622
Self-citationPolydrug abuse: a review of opioid and benzodiazepine combination use
Jones, J. D., Mogali, S., & Comer, S. D. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.07.004 · Cited by 703 · cited 1×
“preciated problem with more cautious prescribing practices and increased vigilance for abusive patterns of use [96,97].”
BackgroundKampman, K., & Jarvis, M. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000166 · Cited by 678 · cited 9×
“should be stepwise, based on a ‘go low, go slow’ plan with 5–10 mg dose changes [9,18,42] over periods of 5 or more days [9,10,42].”
BackgroundInfluentialEap, C. B., Buclin, T., & Baumann, P. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241140-00003 · Cited by 599
Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T., et al. (2007) · Health Technology Assessment · doi:10.3310/hta11090 · Cited by 585 · cited 3×
“Rates of illicit ‘on-top’ opioid use during therapy do not significantly differ between methadone and buprenorphine [12,79], although some studies report treatment with buprenorphine to be associated with lower continued use of”
BackgroundThe clinical significance of drug craving
Tiffany, S. T., & Wray, J. M. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06298.x · Cited by 556
Opioid receptors: Distinct roles in mood disorders
Lutz, P.-E., & Kieffer, B. L. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.002 · Cited by 542
Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence
Uchtenhagen, A. (2009) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-17408 · Cited by 490
Research works printed but not linked: 28
- Auriacombe M, 2017, The Routle, 500
- College of Physicians and Surgeons of British Columbia, 2016, Methadone and buprenorphine: clinical practice guideline for opioid use disorder
- College of Physicians and Surgeons of Saskatchewan, 2015, Saskatchewan methadone guidelines and standards for the treatment of opioid addiction/dependence
- Advisory Council on the Misuse of Drugs (ACMD), 2015, How can opioid substitution therapy (and drug treatment and recovery systems) be optimised to maximise recovery outcomes for service users?
- Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group, 2017, Drug misuse and dependence. Drug misuse and dependence: UK guidelines on clinical management
- Ministry of Health, 2014, New Zealand practice guidelines for opioid substitution treatment
- SAMHSA. Chapter 2. History of medication-assisted treatment for opioid addiction. In: medication-assisted treatment for opioid addiction in opioid treatment programs [Internet]. Rockville; 2005. Available from: http://www.ncbi.nlm.nih.gov/books/NBK64157/
- Gowing L, 2014, National guidelines for medication-assisted treatment of opioid dependence
- Departement for the Treatment of Substance Abuse, 2017, Policy of the department for the treatment of substance abuse: treatment of opioid addiction through psychosocial therapy and maintenance treatment (agonists and partial agonists such as: methadone, buprenorphine/buprenorphine/naloxone)
- The Swedish National Board of Health and Welfare (Support for governance and management), 2016, National guidelines for care and support in cases of misuse and addiction
- College of Psychiatrists in Ireland, 2016, Heal Serv Exec [Internet]
- Meesmann U, 2011, Main DRUID results to be communicated to different target groups
- Maremmani I, 1999, Heroin Addict Relat Clin Probl, 1, 7
- Leavitt SB, 2000, Mt Sinai J Med [Internet], 67, 404
- Walton G, 2015, BMJ Case Rep [Internet], 2015210239
- Soyka M, 2014, Adv Pharmacoepidemiol Drug Saf [Internet], 3
- Hser Y-I, 2014, Natl Inst Heal, 109, 79
- Mattick RP, 2014, Cochrane Database Syst Rev [Internet], 2, CD002207
- Curcio F, 2011, Eur Rev Med Pharmacol Sci, 15, 871
- Parvaresh N, 2012, Addict Heal, 4, 1
- Maremmani AGI, 2011, Ann Gen Psychiatry [Internet], 10
- FDA, 2017, Opioid addiction medications in patients taking benzodiazepines or CNS Depressants : drug safety communication - careful medication management can reduce risks
- Javaher S, 2015, J Pain, 1
- Auriacombe M, 2016, Traité d’addictologie, 307
- Substance abuse and mental health services administration. Medication-assisted treatment for opioid addiction in opioid treatment programs [Internet]. 2014. Available from: http://www.ncbi.nlm.nih.gov/books/NBK64164/%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/22514849
- National collaborating centre for mental health (UK). Drug misuse: opioid detoxification [Internet]. British Psychological Society. British Psychological Society; 2008. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21452460
- Fischer G, 2012, Heroin Addict Relat Clin Probl, 14, 39
- Saulle R, 2017, Cochrane Database Syst Rev, 2017, 4
Cited by
Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic
Dunlop, A., Lokuge, B., Masters, D., Sequeira, M., Saul, P., Dunlop, G., Ryan, J., Hall, M., Ezard, N., Haber, P., et al. (2020) · Harm Reduction Journal · doi:10.1186/s12954-020-00370-7 · Cited by 273
Dopamine and addiction: what have we learned from 40 years of research
Solinas, M., Belujon, P., Fernagut, P., Jaber, M., & Thiriet, N. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1957-2 · Cited by 181
New directions in the treatment of opioid withdrawal
Srivastava, A. B., Mariani, J. J., & Levin, F. R. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30852-7 · Cited by 148
Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice
Kakko, J., Alho, H., Baldacchino, A., Molina, R., Nava, F. A., & Shaya, G. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00592 · Cited by 140
Self-citationDuber, H. C., Barata, I. A., Cioè‐Peña, E., Liang, S. Y., Ketcham, E. M., Macias‐Konstantopoulos, W., Ryan, S. A., Stavros, M., & Whiteside, L. (2018) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2018.04.007 · Cited by 120
“A maximum initial daily dose of 8 to 12 mg of buprenorphine is formally recommended.(40) Nonopioid medications can be used to manage residual withdrawal symptoms.”
Background
Metadata
- Authors
- Dematteis, M., Auriacombe, M., D’Agnone, O., Somaini, L., Szerman, N., Littlewood, R., Alam, F., Alho, H., Benyamina, A., Bobes, J., Daulouede, J. P., Leonardi, C., Maremmani, I., Torrens, M., Walcher, S., & Soyka, M.
- Affiliations
- Department of Addiction Medicine, Grenoble Alpes University Hospital, Grenoble, France
- Centre National de la Recherche Scientifique (FR)
- University of Manchester (GB)
- Addiction Treatment Centre, Biella, Italy
- Hospital General Universitario Gregorio Marañón (ES)
- Applied strategic, London, UK
- Central and North West London NHS Foundation Trust (GB)
- University of Helsinki (FI)
- Assistance Publique – Hôpitaux de Paris (FR)
- Universidad de Oviedo (ES)
- Université de Bordeaux, Bordeaux, France
- ASL Roma (IT)
- University of Pisa (IT)
- Universitat Autònoma de Barcelona (ES)
- CONCEPT, Addiction Medicine, Munich, Germany
- Ludwig-Maximilians-Universität München (DE)
- ORCID
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2017-12-03
- Volume
- 18
- Issue
- 18
- Pages
- 1987-1999
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2769074706
- Cited by
- 141
- References
- 80
- Citations by year
- 2026: 7 · 2025: 18 · 2024: 12 · 2023: 13 · 2022: 23 · 2021: 17 · 2020: 20 · 2019: 16 · 2018: 15
- FWCI
- 13.10
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Consultation of the Doctoral Thesis Database (TESEO) (Ministerio de Educación, Cultura y Deporte) (submittedVersion, cc-by-nc-nd)
- Funders
- Indivior (Expert meeting attendance, no influence on content)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, buprenorphine, methadone, opioid substitution therapy, pharmacotherapy, integrated treatment, psychosocial interventions, drug overdose deaths, craving, dose titration, pregnant women, prisoners, psychiatric comorbidity, treatment guidelines
- MeSH terms
- Mental Disorders, Buprenorphine, Europe, Humans, Methadone, Opioid-Related Disorders, Quality of Life, Consensus, Risk Reduction Behavior, Patient Preference, Opiate Substitution Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. https://app.cochat.ai/papers/10.1080/14656566.2017.1409722
- The paper
- Dematteis, M., Auriacombe, M., D’Agnone, O., Somaini, L., Szerman, N., Littlewood, R., Alam, F., Alho, H., Benyamina, A., Bobes, J., Daulouede, J. P., Leonardi, C., Maremmani, I., Torrens, M., Walcher, S., & Soyka, M. (2017). Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2017.1409722
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.